<DOC>
	<DOC>NCT02576938</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of baricitinib in eczema.</brief_summary>
	<brief_title>A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Have moderatetosevere Atopic Dermatitis (AD), as determined by all of the following: 1. EASI of 12 or more 2. Greater than or equal to 10% of body surface area involvement 3. Diagnosed with AD at least 2 years prior Have a history of inadequate clinical response to other eczema treatments Females who are pregnant or nursing Participants who do not agree to use adequate contraception Are currently experiencing or have a history of: Skin conditions such as psoriasis or lupus erythematosus Skin disease that requires frequent hospitalizations or intravenous treatment Compromised immunity Serious illness that could interfere with study participation, or a clinically important deviation in physical examination, vital sign measurements, electrocardiograms, or abnormalities on laboratory tests Currently experiencing or have a history of: Active or latent Tuberculosis or specific immunity disorders and infections Malignancy or lymphoproliferative diseases in the last 5 years (or cervical, basal or squamous skin cancer reoccurrence in the last 3 years) Human Immunodeficiency Virus (HIV) Hepatitis B, Hepatitis C, or chronic liver disease Have received certain types of vaccinations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Atopic Eczema</keyword>
</DOC>